Longitudinal data show tirzepatide preserves weight‑loss efficacy and reduces diabetes incidence over a three‑year follow‑up, according to a study in the Journal of General Internal Medicine. The report details sustained metabolic improvement and durable safety signals across the cohort, supporting the drug’s role in chronic obesity management and diabetes prevention. Tirzepatide is a dual GIP/GLP‑1 receptor agonist; the dual‑agonist mechanism combines incretin effects to amplify weight and glycemic outcomes. Regulators and payers will likely weigh long‑term efficacy in reimbursement discussions.